FDA cites meta-limitations of Avandia data; Oueries GSK about trial data bias;

> "The case of rosiglitazone underscores the need for a robust evidence base to demonstrate the safety of medicines administered long-term," write Margaret Hamburg and FDA co-authors in the New England Journal of Medicine, of the limitations of the meta-analyses and observational studies conducted on Avandia. Article

> GlaxoSmithKline has until next month to tell the FDA how it plans to investigate concerns of bias in the Record trial the drug giant ran for Avandia, reports the Financial Times. Article

> NIH is funding Mi-Co to develop a digital-pen-based solution for more efficient capture of medical oncology progress notes and clinical trials data. Release

> Oracle has taken the wraps off Agile Product Lifecycle Management (PLM) 9.3.1 for pharma drug development. Release

> CRO Beardsworth will implement the OmniComm AE Reporting System. Release

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.